Ads
related to: darzalex- DARZALEX® Side Effects
Find Information About Side Effects
Patients May Experience
- About DARZALEX®
Learn About a Treatment Method and
How DARZALEX® Works
- Important Safety Info
Learn About Important Safety
Information for DARZALEX®
- Read Patient Stories
Learn About the Treatment Journey
From Real Patients & Caregivers
- Questions for Your Doctor
Find a List Of Questions for You to
Ask Your Healthcare Provider
- For Caregivers
Learn More About How You Can Help
Your Loved One Throughout Treatment
- DARZALEX® Side Effects
Search results
Drugmakers go under the skin, skirting early US Medicare price negotiations
Reuters via Yahoo Finance· 10 months agoInjectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster...
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
Zacks via Yahoo Finance· 4 months agoJohnson & Johnson’s JNJ fourth-quarter 2023 earnings came in at $2.29 per share, which beat the...
Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
Investor's Business Daily· 1 year agoConfusion over new Medicare negotiating plans sent Regeneron Pharmaceuticals and Halozyme...
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
Zacks via Yahoo Finance· 2 years agoHalozyme Therapeutics, Inc. HALO reported third-quarter 2022 adjusted earnings of 74 cents per...
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
Zacks via Yahoo Finance· 1 year agoHalozyme Therapeutics, Inc. HALO reported first-quarter 2023 adjusted earnings of 47 cents per...
Here's The Surprising Driver Of J&J's Second-Quarter Beat, And Why It Didn't Help
Investor's Business Daily· 2 years agoHealth care bellwether Johnson & Johnson topped second-quarter expectations Tuesday, but JNJ stock...
Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 2 years agoIt has been about a month since the last earnings report for Halozyme Therapeutics (HALO). Shares...
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
Zacks via Yahoo Finance· 1 month agoJohnson & Johnson’s JNJ first-quarter 2024 earnings came in at $2.71 per share, which beat the Zacks...
Genmab: Growth Is Still a Better Choice
GuruFocus.com via Yahoo Finance· 3 months agoGenmab AS (NASDAQ:GMAB) is one of the largest Danish pharmaceutical companies focused on developing medicines to treat patients with cancer, multiple...
Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now
Zacks via Yahoo Finance· 9 months agoJ&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma...
Ads
related to: darzalex